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The focus of much scientific and medical research is directed towards understanding the disease process
and defining therapeutic intervention strategies. The scientific basis of drug safety is very complex and
currently remains poorly understood, despite the fact that adverse drug reactions (ADRs) are a major
health concern and a serious impediment to development of new medicines. Toxicity issues account for
∼21% drug attrition during drug development and safety testing strategies require considerable animal
use. Mechanistic relationships between drug plasma levels and molecular/cellular events that culminate
in whole organ toxicity underpins development of novel safety assessment strategies. Current in vitro test
systems are poorly predictive of toxicity of chemicals entering the systemic circulation, particularly to the
liver. Such systems fall short because of (1) the physiological gap between cells currently used and
human hepatocytes existing in their native state, (2) the lack of physiological integration with other cells/
systems within organs, required to amplify the initial toxicological lesion into overt toxicity, (3) the
inability to assess how low level cell damage induced by chemicals may develop into overt organ toxicity
in a minority of patients, (4) lack of consideration of systemic effects. Reproduction of centrilobular and
periportal hepatocyte phenotypes in in vitro culture is crucial for sensitive detection of cellular stress.
Hepatocyte metabolism/phenotype is dependent on cell position along the liver lobule, with correspond-
ing differences in exposure to substrate, oxygen and hormone gradients. Application of bioartificial liver
(BAL) technology can encompass in vitro predictive toxicity testing with enhanced sensitivity and
improved mechanistic understanding. Combining this technology with mechanistic mathematical models
describing intracellular metabolism, fluid-flow, substrate, hormone and nutrient distribution provides the
opportunity to design the BAL specifically to mimic the in vivo scenario. Such mathematical models
enable theoretical hypothesis testing, will inform the design of in vitro experiments, and will enable both
refinement and reduction of in vivo animal trials. In this way, development of novel mathematical model-
ling tools will help to focus and direct in vitro and in vivo research, and can be used as a framework for
other areas of drug safety science.
1. Introduction to adverse drug reactions
and chemical toxicity
1a. Adverse drug reactions
Adverse drugs reactions (ADRs) are a major cause of drug attri-
tion and are a huge burden on healthcare systems. In the US,
ADRs rank between the 4th and 6th leading cause of death.1
The majority of ADRs are predictable, and become apparent
during preclinical and clinical toxicity assessment,2 and those
that manifest in the human population are commonly as a
result of a prescribing error or through drug–drug interactions
(DDIs3). As a consequence of evidence of toxicity, 16 out of 548
(2.9%) new chemical entities that were approved for the US
market between 1975 and 1999 were subsequently withdrawn
from the market, and 56 out of 548 (10.2%) acquired a black
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box warning.4 Excessive dose, drug accumulation and/or the
formation of chemically reactive metabolites (CRMs) have
been implicated in many off-target (including idiosyncratic)
ADRs. Unlike these ‘predictable’ types of ADRs, idiosyncratic
ADRs are rarer but are more likely to be fatal.3 Idiosyncratic
ADRs are often detected only when the offending drug has
been released into the wider population following regulatory
approval. Idiosyncratic ADRs are generally immune mediated
and include hepatotoxicity, severe cutaneous reactions, ana-
phylaxis and blood dyscrasias.5,6
The organ that is most frequently affected by CRM-
mediated ADRs is the liver. Drug-induced liver failure (DILI)
poses a major clinical issue and has become the leading cause
of acute liver failure and transplantation in Western
countries.7,8 DILI accounts for more than half the cases of
acute liver failure in the United States. DILI also represents a
major challenge for industry and regulatory authorities: it is a
leading cause for termination of further substance develop-
ment in preclinical and clinical phases, and it is also the most
common single adverse drug reaction leading to refusal of
market approval. However, in many instances a drug’s hepato-
toxic potential is only recognized post-marketing and DILI has
therefore also been a significant reason for withdrawing drugs
from the market. Acetaminophen (paracetamol; APAP) is
responsible for 80% of drug-associated cases of liver failure.8
APAP-induced hepatotoxicity is generally predictable from our
understanding of its metabolism; however, many other drugs
cause idiosyncratic DILI, which, although rare and unpredict-
able, can cause significant morbidity and mortality. Studies
with model compounds and drugs — such as APAP — have
helped to define the roles that chemical stress and drug bio-
activation have in the various biological outcomes that may be
triggered by CRMs. These include effects on transcription
factors and/or signalling protein-adaptation (cell defence),
apoptosis, necrosis, inflammation and activation of the innate
and adaptive immune systems.9
Many different classes of drugs licensed for clinical use are
known to cause DILI in man, and the cumulative DILI burden
on professional health services coupled with patient well-being
and/or mortality is high. Adverse drug reactions affecting the
liver may be classified in two main types:
• Dose-dependent DILI which can be replicated readily in
various animal species and is evident during preclinical safety
testing.
• Human-specific DILI, which cannot be predicted in
animal models or animal systems, and include idiosyncratic
drug reactions (drug- or individual (Human Leukocyte Antigen
(HLA) restriction)-specific) are unpredictable, occur only in
certain susceptible patients and have a complex dose-depen-
dent relationship.
Over 1000 drugs and herbal products have been associated
with idiosyncratic hepatotoxicity,10–12 which is responsible for
more than 10% of all cases of acute liver failure in the US. The
incidence of idiosyncratic DILI caused by some drugs can be
high as 1 in 100 patients (e.g. chlorpromazine), but more typi-
cally lower at 1 in 10 000 patients (e.g. flucloxacillin).
Idiosyncratic DILI is of major concern because it is not predict-
able from pre-clinical safety assessment studies due to a lack
of predictive models, and consequently is rarely evident until
late clinical trials or after regulatory approval.
Despite extensive work over the past 20 years, no new non-
clinical tests and/or clinical biomarkers have been forthcom-
ing for DILI that have been universally accepted by drug-devel-
opers, clinicians and regulators.13 In vivo safety testing in pre-
clinical species ensures that drugs, which enter clinical trials,
do not cause reproducible and dose-dependent liver injury.
However such test systems have failed to predict some serious
cases of DILI that actually occurred in man, in particular those
of an idiosyncratic nature. An improved understanding of
mechanisms that underlie DILI in man is therefore required to
enable design of drugs that have minimal potential to cause
this adverse reaction in the patient population.
There are a number of different mechanisms through
which drugs and their metabolites have been shown to cause
ADRs. These include mitochondrial injury, transporter inter-
actions, innate and adaptive immune system activation, direct
cytotoxicity and phospholipid/lysosome liabilities. It is beyond
the scope of this review to discuss novel in vitro and mathemat-
ical models for each of these toxicity mechanisms. The devel-
opment of more sensitive in vitro models that replicate the
in vivo environment allows re-investigation of drugs that have
caused serious injury in man or adverse signals in experi-
mental animals. Additionally, closer recapitulation of in vivo
conditions would naturally encompass wider mechanistic cov-
erage. These biological signals may have been overlooked in
previous investigations due to a lack of appropriate technology
or information. More effective in vitro systems would allow
pragmatic compound ranking during drug discovery, aiding
in vitro/in vivo translation with species/dose selection and
translation to man. Therefore, we will focus on novel models
exploring metabolic liabilities of drugs and chemicals. In par-
ticular, the design of in vitro systems that more closely mimic
the in vivo environment, especially with respect to metabolism
and bioactivation, and how these systems can be mathe-
matically modelled.
The concept that small organic molecules can undergo bio-
activation to electrophiles and free radicals, and elicit toxicity
by covalent modification of cellular macromolecules, has its
basis in chemical carcinogenicity and the pioneering work of
the Millers14–16 (who studied the hepatotoxic effects of p-
dimethylaminoazobenzene in the rat and found that aminoazo
dyes become tightly bound to the protein constituents of liver
tissue). The application of such concepts to human drug-
induced hepatotoxicity was established through the studies of
Brodie, Gillette, and Mitchell on the covalent binding to
hepatic proteins of toxic doses (samples were obtained from
overdose patients) of the widely used analgesic APAP. This
concept is now well established, and there is a wealth of evi-
dence to suggest that drug metabolism to a Chemically Reac-
tive Metabolite (CRM; bioactivation) is the initiating step in a
number of direct and immune mediated toxicities.5,17 A
common mechanism for the detoxification of CRM occurs via
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glutathione (GSH) conjugation.18,19 The identification of drug
metabolite-GSH adducts in a preclinical setting is sometimes
treated as a hazard signal as it is indicative of CRM formation;
conversely it could be argued that a GSH adduct is an indi-
cation of an effective detoxification system. Idiosyncratic ADRs
are not reproducible in preclinical species, and so, recently
there has been an increased focus on the development of sur-
rogate endpoints of toxicity (biomarkers; either biological or
chemical), animal models and improved understanding of
structure-activity relationships of drugs. A list of chemical moi-
eties frequently associated with drug bioactivation and sub-
sequent toxicity (structural alerts) has been compiled.17 One
approach to improving a drug’s safety profile would be to
avoid incorporating these structural alerts altogether; however,
these moieties often are key to the pharmacology of the drug.
In addition, the presence of a structural alert does not auto-
matically result in a toxic compound; not all drugs that
contain a structural alert are bioactivated and not all bioacti-
vated drugs are toxic.17 The structure-activity relationships are,
therefore, not straight forward.
1b. Requirement for improved models of hepatotoxicity
The current in vitro test systems used by the pharmaceutical
industry include simple liver-derived cell-based or sub-cellular
models that are poorly predictive of toxicological potential.
Importantly, such models do not take account of the mecha-
nistic basis of human DILI or the environmental conditions
under which human DILI might occur. Critically, there has not
been a concerted effort at harmonisation of current, emerging
and novel test systems, or the strategies for their implemen-
tation, across the Pharmaceutical Industry. As a result, too
little is understood about how the current test systems
compare physiologically with human liver, what are the critical
signalling systems, and the mechanisms by which DILI occurs
in man, to be able to produce more predictive test systems.
It has been estimated that a 10% improvement in predict-
ing failure before the initiation of expensive and time-consum-
ing clinical trials could save upwards of $100 million in the
costs associated with drug development.20 The need for better
predictive models for DILI is clear and obvious. DILI is widely
regarded both during clinical development and post-approval
as a leading cause of:
• Drug attrition due to preclinical toxicity
• Drug attrition due to toxicity in man in late clinical trials
• Drug withdrawal post-licensing
• Cautionary and restrictive labelling
• Failed regulatory drug registration
• Serious illness in man
Therefore, it constitutes a major safety concern for drug
development that severely impacts the profit margins of
pharmaceutical companies through increased costs, longer
development times and reduced market capitalization. Elimi-
nation of drug candidates likely to cause hepatotoxicity at early
stages of drug discovery could significantly decrease the rate of
attrition and cut the cost of drug development. In the context
of prediction of DILI there are numerous issues to solve.
Presently, there is a lack of sufficiently organized data to make
an informed conclusion on the predictivity of non-clinical
studies for identifying the risk of significant hepatotoxicity in
clinical trials and in the post-marketing population. Addition-
ally, there is limited predictive value of animal studies; some
compounds have progressed into human trials and have then
caused severe human toxicities, and no patterns existed in the
animal studies that signalled these events. Currently, retro-
spective studies are being used to shed light on potential
mechanisms that underlie toxicity. Ximelagatran, a first-gene-
ration thrombin inhibitor, was developed as an alternative to
warfarin for individuals requiring anticoagulation therapy.
However, up to 15% of patients treated with this drug experi-
enced elevations in serum ALT levels, which were severe and
life threatening in some cases.21,22 An association between the
HLA class II allele HLA-DRB1*07 and elevations in serum ALT
levels was observed in 74 ximelagatran treated patients, com-
pared with 130 controls who were also given ximelagatran but
who did not develop DILI; these findings were replicated in an
additional dataset.21,22 Neither preclinical nor clinical studies
of ximelagatran had suggested an immune-mediated mecha-
nism underlying the increase in serum ALT levels associated
with the use of this agent. However, studies in guinea pigs had
suggested the possibility of skin sensitization in response to
ximelagatran and some individuals exposed to ximelagatran
during the manufacturing process developed a skin rash.
Additionally, ximelagatran and its metabolites were shown to
selectively inhibit the binding of peptides to HLA-DRB1*0701,
further supporting a role for immune dysregulation in the
pathogenesis of this instance of DILI.21,22 This exemplifies the
fact that human-specific and idiosyncratic hepatotoxicity
cannot be detected by conventional animal toxicity studies,
with there being no suitable preclinical models combined with
a poorly understood pathogenesis. It is likely to arise from
complex interactions among genetic, non-genetic host suscep-
tibility, and environmental factors. Additionally, interspecies
differences in bioavailability, distribution and metabolism
may explain a number of false positives and false negatives.
A much better understanding of the molecular mechanism
(s) of liver toxicity in man, as well as the underlying reasons
why non-clinical studies fail to prevent compounds which
produce serious human hepatotoxicity from proceeding in the
clinic, could result in the development of a more predictive
non-clinical testing strategy. This is a critical prerequisite for
any improvement in the detection of hepatotoxicity during the
pre-clinical phase of drug development. Experimental
approaches have focused on the development of various
in vitro assays that can be used to assess in vivo effects. In vitro
studies on liver cells have been developed to reduce or replace
animal experiments. However, most of the in vitro tests in use
are based on cell lines, which do not necessarily represent
normal cell physiology.
The current in vitro test systems are poorly predictive of toxi-
cological potential for a number of reasons. (1) The physiologi-
cal gap between the cells that are currently used and human
hepatocytes as they exist in their native state; (2) the lack of
Review Toxicology Research
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physiological integration with other cells and systems within
the liver, that are required to amplify the initial toxicological
lesion into overt toxicity, and; (3) there is no way to assess how
low level cell damage induced by a drug may, in certain cir-
cumstances, lead to overt DILI in only a small minority of
patients (i.e. idiosyncratic hepatotoxins). New approaches that
improve upon conventional processes of risk assessment and
safety evaluation are currently sought. Numerous promising
new technologies and approaches have been described or are
being developed which replicate many of the key biological
processes implicated in reproducible and idiosyncratic/
human-specific DILI. These range from simple cell systems to
complex in vivo models, and may have the potential to
enhance prediction and risk assessment of DILI in man if
used during drug discovery and/or pre-clinical development.
The choice of system or model to use depends upon the
biology under investigation, for example in tissue engineering,
it is widely accepted that 3D tissue culture models behave very
differently to 2D models.
1c. Other disciplines to benefit from improved in vitro and
mathematical models of toxicity
Global regulatory bodies require acute toxicity testing. The
classification and labelling of chemicals based upon their
hazardous properties is a major focus for these studies, whilst
extending this information through to risk assessment and
management is being attempted where possible. Although legi-
slative controls around the world differ slightly with regard to
their requirements and the broad hazard categories, the basic
purpose of acute toxicity testing is the same: to allow sub-
stances to be categorised according to their potential hazards
and the dose required to cause toxicity.23 Investigation of the
potential to cause chemically-mediated toxicity is particularly
important with legislation, such as the European Union
REACH and Cosmetics regulations, and the Canadian Danger-
ous Substances List.24 In the EU, REACH is a regulation
adopted to improve the protection of human health and the
environment from the risks that can be posed by chemicals,
while enhancing the competitiveness of the EU chemicals
industry. It also promotes alternative methods for the hazard
assessment of substances in order to reduce the number of
tests on animals. In principle, REACH classification and label-
ling applies to all chemical substances, including industrial
chemicals, biocides, active pesticide ingredients and final for-
mulations, isolated pharmaceutical intermediates, new food
additives, cosmetic ingredients, and consumer products.
Therefore, the regulation has an impact on most companies
across the EU. This legislation will help ensure that all chemi-
cals manufactured or imported will have appropriate toxico-
logy safety profiles.23,24 REACH became law in June 2007. It
stipulates that all chemicals sold in the EU in annual quan-
tities of more than one tonne (at least 30 000 compounds)
must be registered, along with toxicity data, by 2018. When
REACH was taking shape, it was clear that more stringent
chemical-safety testing would require many more tests on labo-
ratory animals. This has raised a number of deep concerns,
principally ethical, but also including the financial costs, or
even whether there were enough laboratories to conduct all the
tests that would be required.25
Clearly, gathering all toxicological information utilizing
animal testing would be costly and carries a significant ethical
responsibility. It is thought that a thorough gap-analysis inves-
tigation of the available toxicological data will highlight areas
of data-deficiency, and rather than conducting further animal
testing, this will enhance the development and validation of
emerging and novel techniques, technologies and platforms,
expanding the chemical and biological knowledge base and
allowing improved prediction of safety. Ultimately this will
enable platforms to be defined to enhance knowledge depth,
as opposed to purely being used for testing. The two main
principles underlying this approach are (1) that similar chemi-
cals should elicit similar downstream toxicological profiles
and (2) both unbiased and case-study approaches are required
to address this issue.26–29 Therefore, chemicals that have well
characterised pharmacokinetic, metabolic and toxicological
profiles can be placed into specific categories, either based
upon similarity profiles across both chemistry and nature of
the downstream biological perturbation elicited. Subsequently,
chemicals with less data available (e.g. only in vitro data) can
be assessed for hazard to man using read-across processes to
fill data deficits in the toxicology allowing enhanced prediction
of safety.27,30 This approach has been shown to be of use to
predict a range of chemicals and toxicological endpoints, such
as skin and respiratory sensitization, mutagenicity and carcino-
genicity, reproductive toxicity, toxicity of petroleum derivatives,
nickel compounds, repeat dose toxicity and acute fish toxicity,
excellently reviewed by the Cronin lab.24,31–34 However, in
order to address these data deficient areas we need more inno-
vative in vitro and in silico approaches that take into account
the mechanistic basis underlying the perturbation of normal
biological processes by drugs and chemicals – in man.
2. Physiological replication in in vitro
models of hepatotoxicity
Current in vitro models offer both a relatively homogeneous
view of liver function and cellular phenotype, when in reality,
the morphology and function of hepatocytes vary enormously
with their position along the liver sinusoids from the portal
triad to the central vein. This phenomenon, termed zonation,
has been described in practically all areas of liver function35
(Fig. 1). Bioenergetic processes, carbohydrate-, lipid-, nitrogen-
and xenobiotic metabolism, bile acid conjugation and detoxifi-
cation processes, have all been predominantly located within
separate hepatic zones. The distribution of function along the
length of the sinusoid is thought to be regulated by diverse
factors such as oxygen and hormone gradients, nutrients and
matrix composition. Importantly, the effects of the aforemen-
tioned factors upon non-parenchymal cell distribution and sig-
nalling, may alter the cross-talk between these cells and
hepatocytes, assisting in defining the ultimate phenotype of a
Toxicology Research Review
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hepatocyte at a particular sinusoidal position. The regional
characterization of hepatic responses to model hepatotoxins is
well described, especially with compounds such as APAP,
which elicits centrilobular hydropic, degenerative necrosis in
the centrilobular zones of rodent and human liver. This necro-
tic pattern is also well characterised for carbon tetrachloride
and bromobenzene in rodents. Less well characterised are the
molecular processes leading to subsequent proliferation in
periportal and midzonal regions in rodents.36 The regional
hepatic injury pattern observed after administration of metha-
pyrilene and allyl alcohol to rats, consists of periportal necro-
sis.36,37 Importantly, differential zonal responses to
hepatotoxins, assists in dissecting more sensitive mechanistic
details, which are highly unlikely to be observed in in vitro
models. For example, the periportal rat hepatotoxin, metha-
pyrilene, elicits initial glutathione depletion in periportal
hepatocytes, whilst stimulating glutathione synthesis and
adaptation in centrilobular hepatocytes. In in vitro hepatocyte
incubations with methapyrilene, this is simply manifest as
glutathione depletion and necrosis, with important adaptive
responses being missed.37 It has been observed with the cen-
trilobular hepatotoxin, APAP, using immunohistochemical
techniques that there were dynamic changes in the lobule
zonation of glutathionylated proteins.38 At 1 h after APAP
exposure, the level of glutathionylation decreased in a single
layer of hepatocytes around the central veins but increased in
the remaining centrilobular hepatocytes.38 The increase corre-
lated with the immunohistochemical localization of APAP
covalently bound to protein.38 Subsequently, the level of gluta-
thionylation decreased over time in the centrilobular regions.
These temporal and zonal pattern changes in protein glu-
tathionylation after APAP exposure indicate that protein gluta-
thionylation may play a role in protein homeostasis during
APAP-induced hepatocellular injury.38
3. Tissue engineering in bioartificial livers
and hepatic bioreactors
In an attempt to replace the use of animal-derived tissue or
in vivo models, numerous bioreactor systems have been used
to engineer liver tissue, to act as an in vitro liver model. In
theory it is possible to replicate the liver environment by
careful selection and control of the cell culture environment in
the bioreactor. Providing the correct environment necessitates
(a) accurate mass transfer mechanisms of chemicals to the
cells and metabolites away from the cells; (b) appropriate physi-
cal conditions, i.e. temperature, pressure, concentration pro-
files, shear stresses, 2D or 3D cell anchorage; (c) appropriate
biochemical conditions, i.e. cell-matrix interactions, cell popu-
lation density, provision of endocrine signalling molecules. All
these factors must be at a size and with dimensions that allow
accurate replication of liver function, both chemically and
spatially, that is zonation ideally needs to be achieved. In the
liver, plasma flows through the epithelial fenestrations and
across the space of disse to the hepatocytes; as such, hepato-
cytes are not in direct contact with the blood flow. It is essen-
tial to replicate the in vivo flow environment if physiological
function is to be achieved in a bioreactor. This is for two key
reasons: fluid shear stresses, and mass transport consider-
ations. If media is in direct contact with the cells, fluid shear
stresses will be exerted on those cells. Shear stress is known to
have an effect on cell behaviour – it has been reported that
media flow upregulates primary human hepatocyte detoxifica-
tion gene expression39 (although these findings may be due to
the concentrations experienced as opposed to shear alone).
Secondly, nutrient (and chemical) delivery/removal to/from the
cell population is a direct function of the flow environment,
given that nutrients and chemicals are transported in a dis-
solved state in the blood plasma. This also has implications
for scale-up of bioreactors to a larger size required for tissue
engineering on a clinical scale, as increased flowrates will be
required to obtain the same media concentration profile.
Bioreactors that have been used to date as in vitro liver
models are summarised in Table 1; while they all have advan-
tages and disadvantages, it is clear that hollow fibre mem-
brane bioreactors (HFB) most closely represent the ideal
design (see Fig. 2 for the setup of a HFB). Only membrane bio-
reactors separate hepatocytes from the main media supply
(although the inner cells in spheroids are also removed from
the flow and will receive media by diffusion) and thus enable
the in vivo fluid shear environment to be replicated. In fact,
shear can be applied independently, if desired, by side ports.
These side ports can be used to supply different media types
as well as apply shear, if desired and can be used to remove
‘bile’. Further, by controlling the media flowrates and press-
ures, the precise flow environment can be prescribed to mimic
the nutrient and chemical delivery environment in vivo.
A major consideration for a liver bioreactor is the replica-
tion of zonation. This was first achieved using a flat plate con-
figuration;40 subsequent designs include the macro-fabricated
Fig. 1 A diagram illustrating the functional units of an hepatic acinus within
liver tissue. An enlarged view of an hepatic acinus containing the portal triad –
hepatic arteriole (1), portal vein (2), bile duct (3), central vein (4) and the direc-
tion of bile (green arrow) and blood (red arrow) flow. Inset. A simplified look at
how the hepatic acini individually contribute to the drainage system within liver
tissue, which is the unit supplied and drained by terminal branches of portal
triad vessels. Nucleus (N), Smooth endoplasmic reticulum (SER), Bile salt export
pump (BSEP), Mitochondrion (M).
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array bioreactor41 (flat bed), and the lab-on-a-chip bioreactors
‘liver chip’ (flat bed) mentioned in the review by Lerapetritou
and co-workers.42 The microfabricated flat plate bioreactors by
Park and co-workers43,44 could also induce zonation, and do
so linearly so that the waste is removed with the media outlet.
Hollow fibre bioreactors build on this and their most signifi-
cant benefit is the fact that they can be operated to replicate
both zonation,45 and the sinusoid physiology. The hollow
fibres, which are porous tubular membranes, act as pseudovas-
cularisation. In the liver scenario each fibre acts as a sinusoid;
given that the fibre walls are porous, media can flow across
them to the cells, but importantly the cells are protected from
the flow of the media in the lumen. This means the media
supply rate can be altered without risk of shear damage to the
cell population. It could be said that cells in spheroids, such
as those recently reported46,47 will experience zonation, as far
as they will experience a concentration gradient as media
diffuses to the centre of the constructs, and waste diffuses
back out. This does not however replicate the linearity of the
sinusoid.
Hollow fibre bioreactors are not without their own chal-
lenges. Achieving homogeneous seeding is more complex than
for a flat surface. Further, there are more components to deal
with than flat sheet/bed bioreactors so the user needs
additional training (and although experience shows that, with
training, fabricating and operating them is possible by a wide
range of users).
Hollow fibre bioreactors have a large surface area to volume
ratio thereby making them space-efficient and more media
efficient, both of which are important from an economic pers-
pective particularly on a larger-scale beyond the lab bench,
and as such they are used for a number of industrial appli-
cations. Hollow fibre bioreactor fluid dynamics and mass
transfer are well characterised due to their use in a range of
fields including waste water treatment, cheese making and
hemodialysis, as well as mammalian cell culture including for
bioartificial livers (BAL) which Wang 201041 covers in a com-
prehensive review. A good introduction to hollow fibre mem-
brane bioreactors can be found in Coulson and Richardson’s
Chemical Engineering Volume 248 and elsewhere for more
detailed design information.49
4. Mathematical modelling for bioartificial
liver and hepatic bioreactor design
To enable broader and interdisciplinary applications of HFBs,
it is essential to tailor the HFB operation to fulfill the
Table 1 Bioreactor designs used for in vitro liver models
Bioreactor design
Is there direct
contact of cells
and media?
Can a second
feed be supplied
to the cells?
Can shear experienced by
the cells be controlled
separately to the media
stream?
Can zonation
be induced?
Can ‘bile’ be
collected
separately to exit
media?
Example
reference for
bioreactor design
Ideal design No Yes Yes Yes Yes
Hollow fibre
membrane
No, except* Yes Yes Yes Yes 125–127*. See
also41 main focus
is BALs128
Rectangular slide
(flat bed)
Yes No No Yes No 40
Macro-fabricated
array bioreactor
(flat bed)
Yes No No Yes No 43,44
Spheroids in a
stirred tank
Yes No No To an extent
through the
spheroid
No 46
Rotating HFB with
cell-cytodex
spheroids
No No Yes To an extent
through the
spheroid
No 47
Flat sheet
membrane
No Yes Yes Yes Yes 129–133
Lab-on-a-chip
bioreactors ‘liver
chip’ (flat bed)
Yes No No Yes No 42
Fig. 2 Sketch of a hollow fibre membrane bioreactor. The hollow fibre mem-
brane acts as the blood vessel through which media is added, with cells cultured
on or around the outside of the fibres. Ports on the sides of the module allow
addition or removal of cells, media, and other components.
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requirements of the application under consideration. One
route to achieve this is through mathematical models that
describe the coupling between fluid and mass transport and
the biochemical and biomechanical environment of the cells.
It is essential that such models provide useable operating
equations to allow accurate operation of the bioreactors by
non-experts, and numerous studies in the literature have
focused on such an approach.
The structure of a HFB is demonstrated in Fig. 2 and 3; it
consists of a bundle of fibres housed in a bioreactor. Each
fibre consists of a central cylindrical lumen surrounded by a
porous membrane, then extra-capillary space (ECS). Cells can
be seeded on the outer surface of the fibres (as relevant for
hepatic considerations), or in a matrix surrounding the fibres,
and media is driven through the fibre lumen under an applied
pressure gradient. Given that the membrane is porous, nutri-
ents, waste products, proteins and chemicals can permeate
across it, to or from the cells. Further, exit ports in the ECS
space may be opened to promote a fluid flow through the cel-
lular space – this may be used to enhance nutrient delivery to
the cell population, or to impose controlled fluid shear forces
to the cells if required by the population under consideration.
Mathematical models for mass transport in these systems are
broadly divided into whether these ports are held shut
(diffusion-limited) or open (convection-enhanced), according
to the fluid flow regime that each scenario promotes. The
general modelling frameworks take the form of convection–
diffusion–reaction equations, where convection is applicable
to the regions of the bioreactor with fluid flow, and the reac-
tion component is used to, for example, describe uptake/pro-
duction of nutrients/waste products by the cell population.
Fluid flow is generally described using either Navier–Stokes or
Darcy equations, depending on whether the flow is free (e.g. in
the lumen), or through a porous medium (e.g. the membrane).
Traditional modelling approaches for HFB have been moti-
vated by understanding mass transport of solutes (e.g. oxygen,
glucose) and proteins in a single fibre unit, called the Krogh
cylinder, which is assumed to be representative of the whole
reactor. The concept of a Krogh cylinder was originally intro-
duced to describe diffusion of oxygen from capillaries in
human tissues,50 and is now a common approach in efforts to
model HFBs.51–55 The model consists of a single fibre sur-
rounded by an annulus of ECS; by assuming the each fibre is
identical and that the fibres are arranged in a regular hexa-
gonal pattern, analysis of transport in this single fibre unit is
considered representative of that throughout the bundle.
One of the earliest examples of the Krogh cylinder approach
is Apelblat et al. 1974,56 where the authors use coupled
Navier–Stokes equations (lumen) and Darcy’s law (membrane
and ECS) to describe fluid transport. In Kelsey et al. (1990),57
Darcy’s law was replaced with Navier–Stokes’ equations for a
setup with no cells in the ECS. Bruining (1989)58 presented a
general description of the hydrodynamics in hollow fibre
devices. The scope of his analysis included different modes of
operation (e.g. ECS ports open or shut) corresponding to
various applications of HFBs. Starting from mass and momen-
tum balance equations, Bruining obtained expressions for the
hydrostatic pressure and bypass (fraction of fluid passing
through the ECS). However, Bruining’s analysis provides no
information on local velocity profiles, which are essential to
understand, control and predict the transport of nutrients or
waste products by advection. A review of Krogh cylinder
models for mass transport in HFBs for cell culture is presented
in Brotherton and Chau (1996).51 Two further Krogh cylinder
approaches modelled the ECS as a porous medium to mimic a
densely packed cell population.55,59 Abdullah and Das (2007)59
consider the impact of multi-solute interactions by using the
Maxwell–Stefan equations to describe diffusion. Numerical
solutions of the full equations using finite-element methods
are used to investigate the dependence of the nutrient concen-
tration profiles on parameters such as the cell density, fluid
flow rate and depth of the cell layer.
Various approaches by the current authors have focused on
the development of equations and data to inform bioreactor
design and operation. One example focused on water transport
throughout a single module unit in the absence of cells;60 this
was integrated with experimental data to determine the per-
meability of poly(vinyl alcohol) (PVA)–PLGA membranes to
pure water transport and to define an operating equation that
relates the input conditions (lumen flow rate, lumen exit
pressure and bioreactor geometry) to the ratio of flow rates
exiting either the lumen and ECS. An extension to this overlaid
a Poiseuille flow model for fluid transport in the lumen with
oxygen transport throughout the bioreactor; this took the form
of an advection–diffusion, diffusion and diffusion–reaction
equations in the lumen, membrane and ECS, respectively. The
system of equations was reduced by exploiting the small aspect
ratio of a fibre to give simplified relationships that describe
the relationship between the oxygen concentration throughout
the ECS, and geometrical (e.g. lumen length, ECS depth) and
operational (e.g. flow rates and pressures) parameters that can
be controlled by the user.61 This work was extended to account
for more complex fluid flow environments in the membrane
Fig. 3 A bundle of HFB demonstrating the principle of Krogh cylinders. One
fibre surrounded by an annulus of ECS can be used to describe the entire fibre
bundle when interstitial spaces between the fibre are ignored. The length of an
individual fibre is denoted L; the radius of the lumen is denoted Rl, whilst the
depth of the membrane and ECS spaces are denoted Rm, Re, respectively.
Review Toxicology Research
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and ECS,62 as are encountered if the ECS ports are opened.
Similar approaches have been tailored specifically to the use of
HFB for BAL applications,45 and to explore zonation.63 Here
the mathematical models described above are used to under-
stand how parameters such as the fluid flow rate and lumen
length can be exploited to setup controlled spatial gradients in
oxygen concentration down the lumen length, thus mimicking
zonation in a hepatic sinusoid.
Crucially, the mathematical modelling frameworks des-
cribed above provide spatial information on the cellular
environment that is costly to achieve experimentally, are cell-
type specific, and provide relationships that enable a user to
tune the bioreactor geometry and operation to the application
under consideration. The further development of these frame-
works provides the potential for sophisticated in vitro liver
models that represent more accurately the physiological and
toxicological scenario in vivo, by coupling spatial features such
as zonation to hepatocyte function. With respect to predictive
toxicology, hepatocyte function, in this case, is more con-
cerned with the enzymes responsible for phase I and II drug
metabolism and drug transporters, rather than the enzymes
catalyzing more physiological processes such as ammonia and
carbohydrate metabolism. Consequently, to build a stable
mathematical modelling framework which is applicable to pre-
dictive toxicology, we require chemically, metabolically and
toxicologically well characterised paradigm compounds with
which to begin populating the framework. One of the most
thoroughly characterised molecules in this respect is APAP. It
is now pertinent to briefly review how APAP causes liver injury
through metabolism and bioactivation, and how emerging
in vitro models can help closely reflect the in vivo situation
both physiologically and toxicologically.
5. Acetaminophen metabolism and
bioactivation in emerging models
5a The normal process of acetaminophen-mediated liver
injury
APAP is a very important and widely used tool to study mech-
anisms underlying the development of hepatotoxicity, injury
progression and adaptation across in vitro, animal and human
systems. It is widely recognised that oxidative metabolism of
APAP to N-acetyl-p-benzo-quinoneimine (NAPQI) is crucial for
the development of hepatic injury. Almost every subsequent
event is still the subject of further research, debate and
complexity.
The use of APAP and its associated metabolism, bioacti-
vation and toxicity is a crucially important benchmark which
can be used to cross-evaluate novel in vitro systems. The exten-
sive APAP metabolism/toxicity literature allows for a thorough
comparison of novel in vitro systems, and the extent to which
they improve upon traditional cell cultures methods or re-capi-
tulate the in vivo environment. Comprehensive multi-para-
metric comparisons with respect to the involvement of phase I
and II drug metabolism (CYP2E1, CYP3A4, glucuronidation
and sulfation), drug transporters,64–66 detoxification processes
(transcription factors e.g. Nrf2), adaptive/regenerative and
overt toxic responses during APAP exposure can be compared
both quantitatively and semi-quantitatively. These in-depth
‘functional’ assessments are far more important and provide
real-life data that can be used for in vivo comparison, than
simple mRNA or protein determinations of whether a enzyme
is present or whether a fluorescent probe substrate can be
handled.
At therapeutic doses, APAP is metabolized predominantly
by the phase II metabolic pathways of glucuronidation and sul-
fation. There is a species- and strain-dependent proportion of
APAP which is metabolized by the phase I cytochrome
P450 metabolic pathway to the reactive metabolite NAPQI,
which is subsequently detoxified by conjugation with GSH.67,68
In higher dose situations, the sulfation pathway becomes satu-
rated with depletion of the sulphate pool, the co-factors of glu-
curonidation become depleted, and hence a larger portion of
APAP is metabolized through the phase I pathway. GSH levels
are limited and once depleted below a critical level NAPQI is
free to react with cellular macromolecules. After formation of
significant quantities of NAPQI, the pathways culminating in
cellular injury have been extensively investigated, but their
contributions to the actual pathogenesis are more
tentative.38,67–69 Based on the weight of evidence, NAPQI binds
to various proteins and disrupts their function, leading to
altered cellular function. However, there are likely to be other
direct or indirect effects of NAPQI leading to cell death, such
as alteration of cellular redox status or disruption of signalling
pathways. Despite the multitude of cellular pathways that have
been shown to play a role in APAP-induced hepatotoxicity, dis-
ruption of mitochondrial function is one of the key
outcomes.38,69–71 After covalent binding and GSH depletion
occur, APAP induces the mitochondrial permeability tran-
sition, which allows the leakage of mitochondrial constituents
into the cytosol. After activation of the MPT, mitochondria
swell, lose membrane potential, and exhibit decreased oxi-
dative phosphorylation and ATP depletion. Finally, depending
upon the species, strain and fed/fasting status there may be a
window where some hepatic apoptosis occurs, which rapidly
degenerates into necrosis.72–74
5b Acetaminophen metabolism and bioactivation in
bioreactors
There are many different ways in which to assess bioreactor
capability, this could be through the investigation of physio-
logical parameters, such as cell viability, albumin production
or urea detoxification. However, in order for hepatic bio-
reactors be useful in predicting chemical risk, the functionality
of the drug metabolising enzymes needs to be an integration
of drug clearance, metabolite formation and relative cytotoxi-
city vs. static cultures. Many publications use cytochrome
P450 transcript or protein level as a marker of cell functional-
ity, which although helpful, are not assessments of enzyme
function. For example, freshly isolated hepatocytes will have a
full message and protein complement, yet are likely to have
Toxicology Research Review
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rapidly decreasing functional cytochrome P450 capability due
to enzyme inhibition by reactive oxygen and nitrogen
species.75,76
In order to assess the relative merits of different bioreactor
formats, it is necessary to utilise paradigm compounds that
have very well characterised in vitro pharmacokinetics and toxi-
city profiles, such as APAP.
Allen et al. (2005)35 employed a flat-plate bioreactor to
impose physiologic gradients over phenotypically stable
hepatocytes and evaluate spatial variations of CYP expression
and toxicity. Perfusion of APAP resulted in a shift in the dose
response such that 20 mM was completely toxic in bioreactor
cultures as compared to 40 mM in static cultures. Also, per-
fusion cultures at 15 mM demonstrated a toxicity pattern
similar to the centrilobular localization seen in vivo. This
in vitro zonal toxicity provides insight into the deleterious
effects of APAP and the factors that contribute to spatial toxicity
which would not be observed in conventional culture models.
Toxic effects in this study are likely due to the depletion of
glutathione, which provides protective inactivation of NAPQI.
Though centrilobular localization of APAP toxicity in vivo has
been attributed to local expression of CYP isoenzymes 2E1 and
3A, reduced oxygen availability in centrilobular regions may
also contribute by depleting ATP and glutathione, or increas-
ing damage by reactive species. A combination of these factors
likely resulted in the regional toxicity observed in reactor cul-
tures under dynamic oxygen gradients. Demonstration of
zonal toxicity in vitro allows decoupling of the effects of CYP
bioactivation and glutathione levels on acute APAP toxicity.35
Hepatocyte sandwich perfusion culture can further improve
long-term liver specific functions in vitro, due to the improved
transport of oxygen and nutrients to the cell surface and
effective waste removal from cellular local environment. Per-
fusion bioreactors have been developed based on conventional
sandwich culture which has a hepatocyte monolayer overlaid
by a collagen gel layer 24 h after seeding.77 However, the per-
fusion flow would introduce the hepatocyte culture to the
effect of fluid-induced shear stress not typically encountered
by the cells in natural liver where hepatocytes are shielded by a
layer of sinusoidal endothelial cells from the direct shear of
the blood flow. High shear stress in perfusion culture could be
detrimental to hepatocyte viability and in vitro functions. In
addition, the integrity of the top collagen layer in direct
contact with media flow may be compromised by the long-
term perfusion that leads to the degeneration of sandwich
matrix and, subsequently, the variation in mass transport of
drug access during drug testing.77
Xia et al. (2009)77 have developed a laminar-flow perfusion
bioreactor for immediate-overlay sandwich culture that mini-
mizes shear stress and preserves the mass transport consist-
ency. The cultured hepatocytes exhibited restored cell polarity,
biliary excretion and maintenance of metabolic functions for
two weeks. Liver specific functions of hepatocytes, such as the
phase I drug metabolic function (e.g. EROD activity) are
reported to be maintained for up to 15 days. The perfusion
culture exhibited a higher sensitivity to APAP-induced toxicity
than the static culture on both day 7 and day 14, attributable
to the well-maintained drug metabolic functions of the sand-
wich perfusion culture. Approximately 60% of cell death was
observed in the perfusion culture treated with 25 mM of APAP
for 24 h. Furthermore, the cell viability in the perfusion
culture after APAP treatment on day 7 and day 14 was similar.
In contrast, static culture treated with APAP on day 7 and day
14 produced highly variable cell viability results.
More recently, Prot et al. (2011),78 have attempted to
combine enzymatic functionality with proteomic and tran-
scriptomic assessment of their flat-bed, HepG2-populated bio-
reactor. Classical studies demonstrating the hepatotoxic effect
of APAP performed in vitro show that cytotoxicity is observed
for a concentration of APAP ranging up to 5 to 20 mM with
interspecies differences. In this case, APAP led to an EC50 at a
1 mM concentration for 72 h of contact only in the micro-
fluidic biochip configuration.78 This result is in accordance
with the toxic plasma level observed in humans and which
ranges between 1 and 2 mM. They did not take into account
the protein binding to APAP. Although APAP has a weak
affinity for plasma proteins (<20%), the protein content
between blood and culture are different. Consequently, the
protein binding quantification will be necessary to fully
confirm that the microfluidic biochip condition is a more
physiological situation.78
This is a particularly encouraging report, as HepG2 cells in
particular are not renowned for their metabolic capability.79
Other hepatic cell lines have been reported to have greater
metabolic functionality, however, this is only when treated
with proprietary dimethyl sulphoxide-containing ‘induction-
media’.79 The recreation of more physiological environment
for hepatic cell lines, including flow, oxygen levels, a 3D
scaffold, the presence of endothelial cells appears to allow
much improved functionality over static cultures. However, the
relative importance of each of these parameters should be
investigated in such a way as to define whether it is crucial for
enhancing metabolism in chemical risk assessment in vitro.
This process will be time consuming and costly to conduct
using experiments alone. In the next Section we discuss the
use of mathematical models to inform cellular pharmaco-
kinetics, using APAP as an example case. Compared to the
mathematical models for transport processes within a bio-
reactor, here we focus on the pharmacokinetic processes
within an individual cell. Such models enable insight to be
gained into the relative importance of the range of metabolic
processes occurring, can be used to test hypothesis in silico,
and also can inform experimental work, thus providing a
useful tool to complement existing experimental techniques.
6. Modelling cellular pharmacokinetics:
paracetamol as a case study
The Hill model is a fundamental analytical component for
many pharmacokinetic–pharmacodynamic mathematical
models.80 It is a mathematical function that relates the uptake
Review Toxicology Research
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rate of a compound to the underlying compound concen-
tration, and has insightful explanatory properties in the cases
of a physicochemical equilibrium:81 for example, in helping to
identify specific aspects of a drug; or comparing drug effects;
or predicting the state of the system under variable conditions;
or identifying an effective dosage regime (see ref. 81 for a
review). Even beyond the equilibrium, the Hill equation has
been shown to be of use, for example see Zhi et al.’s82 pharma-
codynamics model for antibiotic treatment of microorganisms.
Analogies of the Hill function to cumulative probability curves
have also been drawn and the Hill equation has been used to
build probabilistic models, for example see Rougier et al.83 in
which the Hill equation is used as an expression of a cumulat-
ive probability distribution for the occurrence of aminoglyco-
side nephrotoxicity. As Goutelle explains,81 the probabilistic
extension of the Hill equation is an exciting prospect as it may
permit estimation of the probability of an adverse reaction and
can therefore potentially be used to make important clinical
decisions.
Studying dose response models has been found to be
useful in determining safe and hazardous levels and dosages
for drugs. A dose-response curve is a simple graph relating the
concentration of a compound to a given response (e.g. physio-
logical, biochemical etc.). Analysis of dose response curves is
typically performed using regression methods; the curves are
typically fitted to the Hill equation (also known as the four
parameter logistic fit). Over the years, a large number of
studies have used Hill equations for the determination of drug
potency, but there are a number issues related with this
method. Prinz84 points out that Hill coefficients may give
insight into the degree of binding cooperativity but cannot dis-
tinguish between competitive, non-competitive or ortho-, iso-,
or allosteric mechanisms. The Hill function is clearly a simpli-
fication and it is likely that cell responses to toxic chemical
compounds may not follow a simple logistic curve. Variation
in the curve shape, however, has been explored by Levasseur.85
Levasseur85 has fit a number of models to data for seven
anticancer agents against both parental and drug-resistant cell
lines with iteratively reweighted non-linear regression. The key
focus of this work was to model simultaneously both exposure
time and drug concentration, rather than the typical approach
at the time of this study which was to focus on concentration
effect curves (see for example,86). The models used in their
fitting take the form of either single, double or triple hill con-
centration effect curves, to represent either single cell popu-
lation sensitivity or two or three populations of cells with
different sensitivities and heterogeneities of drug responses.
These types of models are useful for quantitative assessment,
for example in assessing a growth-inhibitory effect of agents as
a function of concentration and exposure time, but they can
offer limited insight into underlying physicochemical mecha-
nisms as the Hill parameters in this case have no physical
meaning.
Some previous cellular pharmacodynamic models have
included cellular pharmacokinetics, for example see.87–90
The87,88 models are discussed below. The model by Lankelma
et al.89 incorporates two intracellular components with cell kill
from the anticancer agent doxorubicin taken to be a function
of compartmental concentration. In Lobo and Balthasar,90
delays are used to implicitly account for cellular uptake and
binding for methotrexate.
A pharmacokinetic–pharmacodynamic model has been
developed by Kareh et al.87 for the cellular pharmacology of
paclitaxel with a critical dependency on the cell cycle – in par-
ticular cell cycle checkpoints. Here, cell death is assumed to
occur when a threshold level of a lethal compound is exceeded
once the cell is at a particular cell-cycle checkpoint. An
assumed lognormal probability function for cell survival frac-
tion accounts for cell population heterogeneity. The asyn-
chrony of cell-cycle stages within the cell population is
simplified by defining cell damage as the average over all the
cells in terms of a maximum value of the concentration of the
lethal compound. Experimental observations relating extra-
cellular and intracellular concentrations of paclitaxel in
human breast MCF cell monolayers91 has been used to deter-
mine the cellular pharmacokinetics for paclitaxel. This
assumes equilibrium conditions with depletion, protein
binding etc. ignored. Multiple damage mechanisms are taken
into account corresponding to damage incurring at G1 and
G2M phases of the cell cycle. Additive, where the total damage
is represented as an exponent weighted sum, and independent
damage models are compared. The cellular pharmacokinetics
are based on experimental uptake rates92 but, rather than
model the detailed pharmacokinetics, pharmacological terms
are chosen to represent how the intracellular concentration of
the lethal compound depends on the extracellular concen-
tration. These terms are additionally assumed to decay expo-
nentially over time to represent DNA repair timescales.
Another model for paclitaxel is that by Kuh.91 This model
was based on a deterministic pharmacokinetic system to
describe paclitaxel uptake, binding and efflux from cells. The
key aim of the model was to predict the intracellular concen-
tration of the drug. Ordinary differential equations were used
to describe the changes over time of the concentrations of
extra- and intracellular paclitaxel, total (free plus bound) drug
in media and cells, and free drug in media and cells.
There was an explicit consideration of cell volume, which was
taken to be an exponentially decaying/increasing function of
time due to cell cytotoxicity/cell proliferation – which of these
that occurs depends on different drug concentrations.
Extracellular drug binding was assumed to occur via
Michaelis–Menten kinetics with a constant binding rate.
Similar saturating binding kinetics are assumed to also occur
intracellularly but, in this case, the binding rate was assumed
to increase linearly with time. This was based on experimental
observations showing a linear enhancement of tublin concen-
tration over time with paclitaxel treatment. An additional
linear intracellular binding term was also included to take into
account non-saturable binding. The resulting mass balance
equations are solved numerically and a parameter sensitivity
analysis is performed to explore effects on intracellular drug
accumulation.
Toxicology Research Review
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In the work of Rougier et al.,83 the area under the time con-
centration curve (AUC) of amikacine serum concentrations was
used to calculate the probability of occurrence of nephrotoxi-
city. The AUC is a commonly measured pharmacokinetic
metric used to estimate exposure effects to a drug (e.g. see ref.
89 which notes that cell uptake and cytotoxicity of doxorubicin
depends on the shape of the AUC). However, not all studies
support the idea that cell kill is just a function of the AUC (see
e.g.85,93) but note that many of these studies do not account
for transport of drug into the cells which is suggested be an
important factor.88 El-Kareh investigates the effectiveness of
the AUC-dependent cytotoxicology measure to test anti-tumour
effects to doxorubicin in ref. 88. The model is similar to that
of87 but the principle focus was on the cellular uptake and
cytotoxicity of the drug. Cell cycle effects were also neglected, a
Hill-type dependency of cell survival on drug induced damage
was assumed, cell damage was taken to be an additive sum of
extracellular and intracellular effects, and the dependence of
cell kill was on peak values of concentration rather than on
the AUC. El-Kareh88 reports an overall better fit to in vitro cyto-
toxicity data than compared to previous AUC-dependent
models.
The use of the Hill function, however, is limited in that it
fails to account for underlying physicochemical reactions.
Beyond single or positive cooperative binding interactions the
Hill equation is somewhat of a compromise and, given that
often in pharmacology, binding events are not restricted to
single drug-receptor interactions but are instead more likely to
be aggregated measures of drug effects on a large number of
receptors,81 the Hill equation parameters have very little phys-
ical meaning. We propose that a mechanistic model that
describes the physiochemical interaction at the receptor level
and incorporates explicitly drug transport across the cell mem-
brane and includes extra- and intracellular drug kinetics will
best facilitate the quantitative assessment of drug metabolism.
Cellular uptake data (see for example94 for data on doxorubi-
cin) shows that intracellular drug levels often take on the order
of hours to equilibrate with those extracellularly, suggesting
that it is important to keep track of the non-equilibrium transi-
ent kinetics of uptake and cytotoxicity and therefore we
propose that a non-equilibrium model is often most appropri-
ate. We will now describe an example of a modelling frame-
work that takes into account these factors and we use APAP as
an example compound.
6a Case study: a mathematical model of paracetamol
metabolism
The aim of this section is to illustrate how a mathematical
model can be derived to describe, in simple terms, the meta-
bolism of APAP in hepatocytes. A model that is very detailed,
e.g. one that accounts explicitly for all the genes, proteins,
enzymes etc. involved in a metabolic pathway, will normally be
far too complex to be analysed mathematically and the only
effective means of progress is through simulation using com-
putational methods. However, such models will have many
parameters (e.g. rate constants, initial concentrations) and
consequently there is a huge degree of freedom influencing
model outcome, not least because the values of many of these
parameters will be unknown. Because of the degrees of
freedom, a simulation giving good quantitative agreement
with data does not necessarily mean we have an accurately
parameterised model, as changing the value of one parameter
may be compensated by changing another to obtain equally
good agreement. In such cases, simulating the system in a per-
turbed scenario has limited predictive worth, because, if the
chosen set of parameters is incorrect, the predicted results
may be wildly different to that of reality. In contrast, a simple
model, incorporating only the “major” factors in the system,
has the advantage of being less complex, having fewer para-
meters and having a much greater range of mathematical
methods available for its study. Such analytical methods
provide a deeper understanding of the model, which in turn
provides a deeper understanding in the role of each of the
mechanisms in the system being modelled and, as is hoped,
will offer new insights into the biology. However, in proposing
simple models there is a cost in the exclusion of presumed
“minor” mechanisms, which could mean a loss of quantitative
resolution in the model results. The craft of the modeller is to
derive a model that is balanced in detail and simplicity, which
is inevitably a cyclic process working closely with the experi-
mentalists. The relatively simple model presented below is an
initial venture into modelling APAP metabolism in hepato-
cytes. The model has yet to be analysed and parameterised,
but it serves to illustrate how a metabolic pathway can be
described using a fairly simple mathematical model.
An important step in model development is to establish the
mechanisms that are most likely to be the most important in
governing the process. To this end, a very useful starting point
is to put together a pathway diagram of the process, which can
be clearly understood by both the modellers and experimental-
ists. Once such a pathway is in place then it is usually straight-
forward to write down a system of equations describing the
evolution of the components by, for example, using mass
action laws (Fig. 4 shows the pathway diagram used in the
model described below). In our preliminary model, we assume
that all the components of the APAP metabolic pathway are
well mixed in the cell, or at least well mixed in the local site of
Fig. 4 Diagram summarising the paracetamol metabolism pathway in hepato-
cytes. The italicised capital letters indicate the model variables and the sub-
scripted “k”s are the rate constants for the particular path.
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the cell at which these processes are taking place; this assump-
tion means that we can avoid the added complication of
accounting explicitly the spatial variations of the components.
This means that our main variables only change in time and
the evolution of them can be described in terms of ordinary
differential equations.
We assume that APAP (concentration P) is introduced into a
cell with initial concentration P*0; this will of course vary with
dosage and also will be dependent on the location of the cell
along the hepatic sinusoid (we note that parameters that
depend on location will be denoted with a *). From Fig. 4 we
observe that APAP can be converted to excretory products, via
sulphation and glucuronidation, or react with P450 to form
NAPQI (concentration N). In our first approximation, it is
assumed that P450 and the co-factors involved in glucuronid-
ation are present at such high concentrations as to be little
effected by the metabolism of the drug, i.e. their concen-
trations remain approximately constant throughout. For co-
factors involved in sulphation, the story is expected to be
different, in that their concentrations do change during this
process; consequently, we need to track the concentration of
these compound(s) (concentration S). We will assume also that
NAPQI can spontaneously breakdown, releasing APAP back
into the system. Combining all these assumptions we write
dP
dt
¼ kSSP  kGP  k450*P þ kNN
The concentration of P450 is dependent on location in a
liver lobule, hence the * reaction rate constant k*450.
In the absence of drug, we assume there is a natural turn-
over of the sulphation co-factors, being produced constitutively
at a rate βS and naturally breaks down with decay rate constant
δS. Combining this with the removal by sulphation, leads to
the equation
dS
dt
¼ kSSP þ βS  δSS
As discussed above NAPQI accumulates by the (reversible)
reaction of APAP with P450. It is assumed that it can combine
with GSH (concentration G) to form harmless products or, less
desirable, with proteins-SH to form drug–protein conjugates
(concentration T). There are numerous types of proteins-SH
that will react with NAPQI and we will, for simplicity, lump all
the protein-SH types together. Furthermore, we assume that
there is an inexhaustible quantity of them, and describe the
overall reaction along the toxin branch as a simple NAPQI
decay term. The combination of these assumptions yields
dN
dt
¼ k450*P  kNN  kGSHNG kPSHN
This equation contains the key balance between the success
and failure of the hepatocytes dealing with the build-up
NAPQI effectively. Initially, GSH will be present in “large quan-
tities”, which means that the breakdown of NAPQI will be pre-
dominantly along the branch towards non-toxic products.
Mathematically, this says that the quantity kGSHG is much
larger than kPSH. However, as G is being consumed and even-
tually exhausted, then this relationship will switch and the
branch towards drug–protein conjugate production will
dominate.
As with the sulphation compounds, we assume in the
absence of APAP GSH is produced at a constitutive level (at
rate β*G) and decays naturally (with decay rate constant δG),
so that the concentration of GSH in healthy liver cells will be
β*G/δG. We note that GSH levels do vary in the lobule, which we
have assumed to be due to differences in production rate.
Combining this with reaction of NAPQI yields
dG
dt
¼ kGSHNGþ βG* δGG
The build up of drug–protein conjugate, T, will reflect on
the amount of damage the APAP dose will do to the cell. It is
only produced by the reaction between NAPQI and protein-SH
and we write
dT
dt
¼ kPSHN
We have not considered any further reactions involving the
drug–protein conjugate, and the variable T represents an accu-
mulated total concentration of toxic species, rather than the
amount of drug–protein conjugate at a particular time point;
we could add a decay term to this equation as a simple way to
describe these reactions. In order to complete the model we
need to introduce an initial state, say at t = 0; we assume that
the hepatocyte starts off as being healthy and is dosed with
APAP, and write P(0) = P*0, S(0) = βS/δS, N(0) = 0, G(0) = β
*
G/δG
and T(0) = 0.
This relatively simple model consists of ten reaction rate
constants. Parameterisation of models such as these always
poses a challenge and an extensive trawl through the experi-
mental literature will be required to find as many suitable esti-
mates as possible. This process will help to identify
deficiencies in data and motivate further experimentation.
Moreover, the model is simple enough to study using a range
of mathematical techniques, in which we may be able to esta-
blish a full understanding of how the parameters affect the
predicted outcome, for example, deriving a simple formula
that predicts the extent of damage given a dose of the drug.
7. Use of population IVIVE-PBPK
approaches in assessing drug/chemical
toxicity
Given the wealth of mathematical and experimental models
now available to explore hepatocyte function, a key question is
how to relate this in vitro information to the human physio-
logical environment in vivo. One solution to this is the use of
in vitro–in vivo extrapolation (IVIVE) techniques coupled with
physiologically based pharmacokinetic models, and this
approach is now routinely used as a tool to simulate and
Toxicology Research Review
This journal is © The Royal Society of Chemistry 2013 Toxicol. Res., 2013, 2, 40–59 | 51
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
8 
A
ug
us
t 2
01
2.
 D
ow
nl
oa
de
d 
on
 1
1/
11
/2
01
5 
11
:5
3:
48
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
model the exposure of drugs following dosing to humans
and pre-clinical species.95–100 The combination of these
approaches allows the systemic concentration and tissue levels
of the drug/chemical of interest to be simulated. The concen-
trations in the various tissues can be coupled to pharmaco-
dynamic models to simulate pharmacological and
toxicological effects of the drug/chemical in addition to the
pharmacokinetics of compounds.
The basic principles of IVIVE include making in vitro
measurements of the rate of drug/chemical metabolism,
measuring (or predicting) the binding of the drug to plasma
proteins and the non-specific binding within the experimental
in vitro system and a knowledge of the blood : plasma ratio of
the compound. Using physiological scaling factors such as the
amount of microsomal protein or number of cells per gram
tissue together with the weight of the organ the in vitro meta-
bolism data can be scaled up to give an estimate of the intrin-
sic clearance of the drug/chemical in the whole organ. By
incorporating this information into a model accounting for
blood flow through the organ the clearance of the drug in the
organ can be predicted.101
The second characteristic of the drug/chemical that needs
to be understood to use PBPK approaches is the distribution
of the drug/chemical into the tissues of the body. Tradition-
ally, this information could only be generated by performing
studies in animals where compounds were administered
(often by infusion to steady state) then animals were eutha-
nized and plasma and tissues removed and the drug concen-
trations measured. This allowed calculation of the
tissue : plasma ratio in each organ.95 Although many PBPK
models have been constructed using this approach (e.g.102) the
experimental work needed to construct a PBPK model was
laborious, time consuming and required extensive experimen-
tation in animals. Another limitation was that the experiments
needed to be performed for each compound of interest and as
such was not suited to the rapid evaluation of large numbers
of compounds needed in a drug discovery environment. In
recent years in silico methods have been developed that allow
the tissue : plasma ratios for compounds to be predicted
using a knowledge of the compounds physicochemical
properties.103–108 This has revolutionised the use of PBPK
models within the Pharmaceutical industry as for a given com-
pound routinely measured physicochemical data (log D, pKa,)
and in vitro data (plasma protein binding; blood : plasma
ratio) can be used to predict the distribution of drugs into
tissues. By combining the IVIVE approaches to predict CL and
in silico approaches to predict tissue distribution the disposi-
tion of a drug/chemical can be simulated. Furthermore, if
information on the variability of each of the parameters used
in the model is known then it is possible to apply IVIVE-PBPK
approaches to predict the exposure (and effects) of drugs and
chemicals in populations rather than in an “average”
individual.101
As exemplified below this population IVIVE-PBPK approach
has been recently applied to understand the toxicological risk
posed by some drugs and chemicals and some aspects of the
application of population PBPK approaches in human risk
assessment have been recently reviewed.109
Example 1: linking in vitro toxicology data with population
IVIVE approaches
The 2007 report Toxicity Testing in the 21st Century: A Vision
and a Strategy argued for a change in the way that toxicity
testing of environmental agents was performed with a move
away from in vivo animal testing towards toxicity testing based
on understanding pathway perturbations observed in human
cells in vitro with tests being done in a high throughput
format. This high throughput in vitro testing paradigm is now
being utilised in both the Toxcast (US EPA) and Tox 21 (NIH)
programs.110,111
Although the in vitro assays can give a measure of the
hazard posed by individual chemicals, prioritisation of chemi-
cals based only on the toxic concentrations in in vitro assays
without considering the impact of bioavailability, clearance,
and exposure could over- or under-estimate the potential risk
of these chemicals to human health.112
A number of studies have been conducted to try and link
IVIVE-PBPK approaches with high throughput toxicity testing
results to estimate the exposure/dose that would lead to toxi-
city in the more susceptible individuals in a simulated human
exposure. The information from the population IVIVE-PBPK
approach is compared with an estimated of the actual exposure
in human populations. By comparing the window between
simulated and actual exposure the compounds where toxicity
is most likely can be selected for further, more definitive
testing.27
This strategy was exemplified in a study by Rotroff et al.
(2010).113 In this study metabolic clearance was measured in
primary human cryopreserved hepatocytes and plasma protein
binding was measured in vitro for 35 Toxcast chemicals. The
metabolism and binding data were used as inputs in the
Simcyp population-based IVIVE programme.114 Renal clear-
ance was estimated from the glomerular filtration rate and
protein binding and absorption was assumed to be 100%.
From this the human equivalent dose to produce a steady state
in vivo concentration equivalent to the concentration causing
50% of the maximum activity in vitro or the lowest effective
concentration values from the Toxcast data could be calcu-
lated.113 These doses were then compared with chronic aggre-
gate human oral exposures (where known) to see if biological
activity and exposure overlapped. This occurred for only 2 com-
pounds which would not have been at the top of the list based
only on in vitro potency criteria.
In a follow-up study Wetmore et al.29 extended the in vitro
measurements to a total of 239 compounds. In addition to
hepatocyte stability and plasma protein binding in this study
Caco-2 permeability data and blood : plasma ratio data was
also generated for some compounds. For 18 (9.9%) chemicals,
where data was available, the estimated (from IVIVE-PBPK)
dose that would exert a biological effect in the population was
equivalent to or less than the highest exposure estimates in
the US population. The biological effects perturbed included
Review Toxicology Research
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cell growth kinetic effects, alterations in cytokine and drug
metabolising enzyme/transporter expression and CYP inhi-
bition, also affected were prostaglandin E receptor and uro-
kinase-type plasminogen activator, which were both down
regulated. Judson et al.,111 have also reported case studies
(bisphenol A estrogenicity and for conazole CAR/PXR acti-
vation) where the ability of the population IVIVE-PBPK
approaches to predict doses that would perturb the biological
pathway was compared with the doses derived from animal
toxicology studies.
Population IVIVE-PBPK approaches are also being utilised
in an EU funded framework 7 project (predict-IV). (http://www.
predict-iv.toxi.uni-wuerzburg.de). The overall aim of the
project is to develop strategies that improve safety assessments
in the late discovery-early development stage of the drug dis-
covery process. To do this a combination of non-animal based
in vitro test systems (including high content screening),
mechanistic toxicology approaches (including toxicogenomics
and metabolomics analysis) together with in silico modelling
approaches are being utilised.
Example 2: using population IVIVE-PBPK approaches to define
the window between efficacious dose and the doses where
adverse effect are expected to occur
A second utility of population IVIVE-PBPK modelling was
described by Shaffer et al. (BDD 2012). During a discovery
project looking to nominate an α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPA) receptor modulator for
advancement into human trials, as a possible treatment for
CNS disorders, three potential compounds were identified.
Using available in vitro data on the metabolism and binding of
the compounds in humans, together with information on the
potency of the compounds and the plasma levels at which the
compounds caused beneficial and adverse events in pre-clini-
cal species the following strategy was employed. Simulations of
the pharmacokinetics and expected population variability of
the three compounds were made using the Simcyp simulator.
Simulations were conducted to define the doses at which the
plasma concentrations achieved the estimated efficacious con-
centration. The maximal concentrations (Cmax) in these simu-
lations were also compared to the plasma levels at which
adverse events were anticipated to occur. By doing this it was
possible to rank the compounds and to identify the compound
that was predicted to have the biggest window between
expected efficacious dose and the dose at which adverse events
were expected to occur in humans.
Example 3: using population IVIVE-PBPK-PD approaches
Attempts have also been made to use concentrations from
IVIVE-PBPK simulations as input (driving) concentrations for
more sophisticated pharmacodynamic models. An example is
combining the concentrations of basic drugs in the plasma
and heart with in silico population models of the cardiac
myocyte (Polak et al., Toxicology Mechanisms and Methods,
2012; 22, 31). This approach then allows the relationship
between drug concentration and changes in cardiac action
potential to be modelled by considering for instance the
pharmacological consequences of inhibition of the sodium
and potassium channels in the heart.115
As greater application of IVIVE-PBPK approaches to tackle
toxicological problems are made there is a great opportunity to
use the models to help reduce the needs for in vivo testing of
chemicals in animals, and also to make greater use of these
approaches to predict the likely toxicity of chemicals in
humans. For instance Tonnelier et al.,116 have examined the
ability of IVIVE-PBPK approaches to predict human bioaccu-
mulation of environmental chemicals whilst Tan et al.,117 have
discussed the challenges with extending these approaches to
look at the interaction between and subsequent toxicological
outcome when chemical mixtures are dosed rather than indi-
vidual chemicals.
Although the PBPK models currently used provide useful
information further refinements of the models have been
suggested including alternative representations of the tissue
compartments118 and it is likely that to understand some of
the more complex aspects of drug/chemical toxicology more
detailed models that can account for differences in zonation
across the liver, specific sub-populations of cells that are at
risk of toxicity etc will be needed to accurately predict the
relationship between tissue concentration and toxicity in sus-
ceptible individuals. In addition the challenges that need to be
resolved to allow the use of IVIVE and PBPK approaches in
formal human health risk assessment have been recently dis-
cussed.119 Whilst the combination of high throughput in vitro
toxicity data with population IVIVE approaches is showing
great promise particularly as a tool to prioritise compounds for
further consideration there are some limitations of the high
throughput screening approach. These include the fact that
most of the cell types used in high throughput assays lack the
ability to catalyse chemical biotransformation (particularly at a
quantitatively relevant rate) and as such often will only allow
information on parent compound (not more or less toxic
metabolites) to be made. In addition using only a single cell
type as is often done then a number of paracrine signalling
pathways may be missing and in order to restore these, a
mixture of cell types, appropriate extracellular matrices and
three dimensional geometries may be needed. Both of these
limitations outline the need for more complex in vitro systems
that can be used to generate detailed mechanistic understand-
ing of the toxicological risk of compounds identified in the
initial screening approach.
8. Adding value through multidisciplinary
and 3Rs approaches
The concept of the replacement, reduction and refinement of
animals in research (the 3Rs) was first set out in 1959.120
These principles, which provide a scientific and ethical frame-
work for the humane use of animals in research, have long
been embedded in UK and European legislation on the use of
animals in scientific procedures. However, for a long time they
Toxicology Research Review
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have to some extent been seen as a marginal activity, and it is
only now that they are being recognised more widely as a legiti-
mate scientific goal that can provide benefits not just in terms
of animal welfare but also providing more predictive or
efficient tools that benefit science and business.
Within the field of toxicology, studies have traditionally
been conducted in animals at high doses with default
methods used to extrapolate to low level exposures in human
populations. However, there is growing interest in developing
new approaches that could revolutionise how toxicity testing is
conducted. In addition to animal welfare considerations, there
are a number of economic, legislative and scientific drivers for
this e.g.: (i) in vivo toxicity studies are expensive and time con-
suming, which limits their practicality in large-scale chemical
testing programmes such as REACH; (ii) recent changes to the
European Cosmetics Directive prescribe a ban on animal
testing and the marketing of products containing ingredients
tested on animals; (iii) the animal data can be difficult to inter-
pret in terms of predicting potential effects in humans.
In 2007 the US National Research Council (NRC) published
a landmark report on ‘Toxicity Testing in the 21st Century: A
Vision and a Strategy’.121,122 The NRC was tasked with consid-
ering how toxicity testing could incorporate recent advances in
science and technology in order to generate more relevant data
for risk assessment, expand the number of chemicals of
concern that could be assessed, and reduce the time, money
and number of animals involved. The report sees a future in
which routine toxicity testing would be conducted in primary
human cells, human tissue surrogates, or human cell lines
in vitro by evaluating cellular responses in a suite of toxicity
pathway assays. These tools would enable risk assessors to
focus on predicting exposures that are expected to be without
adverse consequences, rather than making predictions on the
incidence of specific adverse responses in human populations.
Implementing this Vision will require a major research
effort involving scientists from a broad range of disciplines
and sectors. Key elements to its realisation include identifi-
cation and understanding of toxicity pathways, plus the develop-
ment of systems to understand exposure parameters in vitro
and their extrapolation to inform safe in vivo exposure/in use
scenarios. A number of research efforts are currently ongoing,
with some taking a case study approach with a specific toxicity
pathway, and others applying a more unbiased approach
seeking to design convenient in vitro systems that would
provide information on as much of the biological response
landscape as possible.27,123,124
The UK National Centre for the Replacement, Refinement
and Reduction of Animals in Research (NC3Rs) works closely
with scientists in industry, academia and government organi-
sations to identify opportunities to minimise animal use and/or
improve welfare, using the 3Rs as a framework to drive inno-
vation. In 2011, the Centre launched CRACK IT (http://www.
crackit.org.uk), a new open innovation programme designed to
accelerate the application of the 3Rs by fostering and funding
multidisciplinary collaborations that broaden the expertise
involved. A central component of CRACK IT is a new
challenge-led research competition, CRACK IT Challenges. For
this competition, the NC3Rs works closely with companies
from the pharmaceutical, chemical, agrochemical and consu-
mer product industries to identify global business challenges
relating to the use of animals. Challenges are supported by
funding from the NC3Rs and in-kind contributions from
industry such as data, compounds and equipment.
The 2011 CRACK IT Challenges competition included a
Challenge seeking to stimulate further research to explore a
pathways approach to safety risk assessment. The research
award was made to the authors of the present paper, on the
strength of the truly multidisciplinary approach proposed;
integrating new tissue engineered liver models based on
human cells with mathematical modelling in order to promote
liver zonation and explore effects on biological pathways
associated with liver toxicity. The various approaches will ulti-
mately be combined with the aim of extrapolating from in vitro
to make decisions around safety in humans. This CRACK IT
project will, if successful, provide proof of principle that the
pathways approach proposed as a means of replacing animals
in toxicology studies can be successfully employed. This
project is complementary to and collaborative with the esta-
blished Hamner DILIsim project and the new Innovative Medi-
cines Initiative project “Mechanism-Based Integrated Systems
for the Prediction of Drug-Induced Liver Injury” (MIP-DILI).
9. Summary – predicting systemic toxicity
with a combined approach
The need for better predictive models for systemic toxicity is
clear. There needs to be an appreciation that organ toxicity is a
spectrum of biological processes from effects on single path-
ways in single cells (e.g. hepatocytes) to complex, time-depen-
dent multi-cellular processes (e.g. innate immune-mediated
injury). Cell injury can result from exposure to chemicals, is
not a single biological process and involves interplay between
chemical and biological factors. Key technology is the pro-
duction and application of zonated hepatic bioreactors,
enabling culture with enhanced physiological and toxicological
representation. Bioreactors have been shown to be superior
over collagen/matrigel adherent cell culture for facilitating the
development of normal cellular function, e.g. resynthesis of
cytochrome P450 enzymes post-isolation. Bioreactors need to
be utilized which reproduce physiological (oxygen/glucose con-
sumption, urea/albumin production) and functional (CYP-
mediated metabolism) hepatic zonation. Future approaches
should be underpinned and informed by a strong mathemat-
ical modelling/systems biology approach that will form a data
framework consisting of circulating drug and metabolite
levels, tissue/cellular burden of metabolites, glutathione and
covalent binding levels, adaptive responses (Nrf2/NFkB
nuclear translocation), apoptosis and necrosis biomarkers,
this would allow more accurate in vitro to in vivo extrapolation
to both animals and man. Chemical engineering has the tools,
in the form of ‘unit operations’, i.e. linked but discrete events,
Review Toxicology Research
54 | Toxicol. Res., 2013, 2, 40–59 This journal is © The Royal Society of Chemistry 2013
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
8 
A
ug
us
t 2
01
2.
 D
ow
nl
oa
de
d 
on
 1
1/
11
/2
01
5 
11
:5
3:
48
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
to describe chemical processes, in this case systemic toxi-
cology. The units in this system are the tissue bioreactors,
focusing on the liver unit, yet expandable to other tissues.
Mathematical modelling should be designed to both provide a
framework with which to perform gap analysis, preventing the
duplication of experiments, but also to mimic the structure of
the experimental work allowing use of cell-scale modelling to
understand metabolite interactions, extrapolation of the cell-
scale behaviour to a liver tissue bioreactor and incorporation
of co-culture/multiple bioreactor units.
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